Over the past few years, several studies have demonstrated the efficacy of sotorasib and adagrasib in patients with KRASG12C-mutant solid tumours, leading to the FDA approval of both inhibitors for patients with advanced-stage non-small-cell lung cancer (NSCLC) harbouring this alteration and who have received at least one prior line of therapy. However, single-agent treatment with these agents provides limited clinical benefit. Now, data from a phase I trial show that the novel KRASG12C inhibitor divarasib is tolerable and has promising activity in patients with KRASG12C-mutant solid tumours.